$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Hologic beat Q3 expectations and raised guidance, but margin compression and weak organic growth—especially internationally—raise concerns about earnings quality and future sustainability.

# Hologic Delivers Q3 FY2025 Beat, But Margin Compression and Organic Growth Headwinds Temper Outlook

---

## Executive Summary

- **Hologic (HOLX) reported Q3 FY2025 revenue of $1,023.8 million and non-GAAP EPS of $1.08, both exceeding consensus expectations and company guidance.** The outperformance was driven primarily by acquisitions and international expansion, rather than underlying organic growth.
- **Earnings quality was mixed:** While GAAP operating margin improved by 80 bps to 24.9% (aided by lower impairment charges), non-GAAP operating margin declined by 110 bps to 30.1% due to acquisition dilution and a less favorable product mix. Non-GAAP gross margin also compressed by 80 bps YoY to 60.3%.
- **Management struck a cautiously optimistic tone,** highlighting strength in Diagnostics and Surgical segments and expressing confidence in a Q4 rebound, particularly in Breast Health. FY2025 revenue and EPS guidance were raised, but management acknowledged ongoing international and margin headwinds.
- **Risks remain underappreciated:** Organic revenue declined 0.8% YoY (excluding COVID, divested/acquired), and international markets—especially China—continue to weaken. Margin compression, rising short interest, and a recent downward revision in analyst price targets suggest the market may be overlooking underlying challenges.
- **Catalyst watch:** Investors should monitor Q4 margin trends, the pace of organic recovery in Breast Health, and the impact of tariff mitigation efforts. The sustainability of cost controls and integration of recent acquisitions will be key to the FY2026 outlook.

---

## Performance Snapshot

| Metric                | Reported    | Consensus   | Surprise   | YoY Change      |
|-----------------------|-------------|-------------|------------|-----------------|
| Revenue               | $1,023.8M   | ~$1,000M    | +2.4%      | -0.8% organic*  |
| Non-GAAP EPS          | $1.08       | $1.01       | +6.9%      | -              |
| GAAP Operating Margin | 24.9%       | -           | -          | +80 bps         |
| Non-GAAP Op Margin    | 30.1%       | -           | -          | -110 bps        |
| Non-GAAP Gross Margin | 60.3%       | -           | -          | -80 bps         |
| China Revenue         | <$10M/qtr   | -           | -          | >-50% YoY       |

*Organic revenue excludes COVID, divested/acquired businesses.

---

## Earnings Quality

- **Revenue growth was acquisition- and internationally-driven,** with organic revenue declining 0.8% YoY. This signals underlying demand softness, particularly in the Breast Health segment and international markets.
- **Margin quality was mixed:** GAAP operating margin improved due to lower impairment charges, but non-GAAP operating and gross margins both declined, reflecting cost pressures and a less favorable product mix. Recent acquisitions contributed to margin dilution.
- **Cost structure:** While management emphasized disciplined cost control, increased SG&A, labor, and logistics expenses weighed on profitability. One-off tariff mitigation provided some margin relief.

---

## Management Commentary & Guidance

- **Tone:** Management was cautiously optimistic, highlighting robust performance in Diagnostics and Surgical, and expressing confidence in a Breast Health rebound. However, they were defensive regarding international headwinds and margin pressures.
- **Guidance:** FY2025 revenue and EPS guidance were raised, with management citing tariff mitigation and cost control as levers for Q4 EPS growth. The company signaled confidence in near-term momentum but acknowledged ongoing challenges in organic growth and international markets.

---

## Key Risks

- **Margin compression** from unfavorable product mix and acquisition dilution.
- **Continued organic revenue weakness,** especially in Breast Health and international markets (notably China).
- **Cost inflation** in SG&A, labor, and logistics.
- **Rising short interest** and downward analyst price target revisions, indicating growing market skepticism.

---

## Expected Market Reaction

- **Cautious optimism is likely:** The market may initially reward Hologic for its headline beat and raised guidance, but concerns over margin compression, organic growth headwinds, and international weakness could temper enthusiasm.
- **Analyst sentiment remains mixed,** with some upward price target revisions but an overall downward trend in consensus targets, reflecting skepticism about the sustainability of recent performance.

---

## Final Takeaway

- **Q3 FY2025 was a strong quarter on the surface,** with beats on revenue and EPS and raised guidance. However, the underlying quality of earnings is fragile, with margin compression, organic revenue declines, and international headwinds persisting.
- **The market may be overvaluing headline results and underappreciating risks** around margin sustainability and organic growth. Investors should watch for Q4 margin trends, the pace of Breast Health recovery, and the impact of tariff mitigation and acquisitions on FY2026 performance.
- **Upcoming catalysts:** Q4 earnings report (margin and organic growth focus), integration updates on recent acquisitions, and any further guidance revisions.

---

Hologic (HOLX): Margin Pressure Offsets Q3 Beat

Hologic faces stabilizing revenues but ongoing margin pressures, with inventory build and segment shifts creating both risks and opportunities ahead of Q3 FY25 earnings.

# Hologic, Inc. ($HOLX): Navigating Margin Pressures and Segment Shifts Amid Global Headwinds – Q3 FY25 Earnings Outlook

## Executive Summary

We maintain a **Neutral** outlook on Hologic, Inc. ($HOLX) for the upcoming Q3 FY25 earnings, as the company faces a mix of stabilizing core segment growth and persistent external pressures. **Revenue is expected in the $1.00B–$1.01B range**, reflecting a modest sequential decline from Q2’s $1.05B, while **adjusted EPS guidance of $1.04–$1.07** signals continued margin compression. Notably, **Diagnostics (+0.8% YoY) and Surgical (+4.2% YoY) segments are offsetting a 7.4% YoY decline in Breast Health**, supporting a more resilient revenue mix. However, the market may be underestimating the impact of **proactive inventory build (+$41.8M YTD)**, which positions Hologic to capture pent-up demand but also introduces near-term working capital risk.

## Recent Trends Signal What’s Next

Hologic’s last two quarters highlight a **stabilization in core segments** but also underscore ongoing margin headwinds. **Q2 FY25 revenue of $1.05B** outperformed consensus, yet **GAAP net margin fell to –1.73%** due to impairment charges, while **non-GAAP operating margin held at ~30%**. The **Breast Health segment’s 7.4% YoY decline** remains a drag, but **Diagnostics and Surgical growth** are providing a partial offset. The following table summarizes the last four quarters’ key financials, illustrating the trend of revenue stabilization and margin compression:

### Quarterly Financial Trends

| Quarter   | Revenue ($M) | Gross Margin (GAAP) | Operating Margin (Non-GAAP) | Net Margin (GAAP) | Adjusted EPS ($) |
|-----------|--------------|---------------------|-----------------------------|-------------------|------------------|
| Q3 FY24   | 1,020        | 38.2%               | 31.2%                       | 5.1%              | 1.08             |
| Q4 FY24   | 1,030        | 39.0%               | 31.0%                       | 6.0%              | 1.10             |
| Q1 FY25   | 1,040        | 37.8%               | 30.5%                       | 4.2%              | 1.05             |
| Q2 FY25   | 1,050        | 37.5%               | 30.0%                       | –1.73%            | 1.03             |

**Key takeaway:** Revenue is stabilizing, but margin pressure is persistent, with impairment charges and segment mix weighing on profitability.

## Management’s Forward Tone and Positioning

Management’s Q2 FY25 commentary reflects **measured optimism** amid external volatility. The CEO noted, “We’re making progress, but it’s been a tumultuous few months from a macroeconomic and policy perspective.” This contrasts with the more upbeat tone of prior quarters, where management emphasized “robust demand and strong execution.” The **downward revision of FY25 EPS guidance to $4.15–$4.25 (from $4.25–$4.35)** and Q3 EPS guidance of $1.04–$1.07 indicate a more cautious approach, with explicit references to “geopolitical and regulatory headwinds in China and Africa.” The shift in tone signals a focus on **cost discipline and operational resilience** rather than aggressive growth.

## KPI Trends & Upcoming Quarter Drivers

Three KPIs are central to the Q3 FY25 outlook:

- **Inventory Build:** **+$41.8M YTD** (up 8% QoQ), supporting near-term sales but increasing working capital needs.
- **Accounts Receivable:** **+$45.4M YTD** (up 9% QoQ), reflecting higher sales volume but also potential cash flow drag.
- **Short Interest:** **Down 20% QoQ to 3.14% of float**, indicating stabilizing sentiment.

### KPI Movement Table

| KPI                   | Q2 FY24 | Q1 FY25 | Q2 FY25 | YoY Change | QoQ Change |
|-----------------------|---------|---------|---------|------------|------------|
| Inventory ($M)        | 510     | 540     | 551.8   | +8.2%      | +2.2%      |
| Accounts Receivable ($M)| 480   | 510     | 525.4   | +9.4%      | +3.0%      |
| Short Interest (%)    | 4.2     | 3.9     | 3.14    | –25%       | –20%       |

**Implications:** Elevated inventory and receivables may support revenue but could pressure free cash flow and margins if demand softens or collections slow.

## Missed by the Street

A key overlooked signal is the **strategic inventory build**. While consensus focuses on margin compression, management’s “making progress” language and the $41.8M inventory increase suggest Hologic is positioning to capture demand surges, particularly in Diagnostics and Surgical. This operational flexibility could mitigate supply chain disruptions—a nuance not fully reflected in current estimates. Additionally, the **declining short interest** signals improving investor confidence, which may cushion the stock against near-term earnings volatility.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($B) | Adjusted EPS ($) | Non-GAAP Operating Margin | Key Assumptions                                      |
|----------|--------------|------------------|--------------------------|------------------------------------------------------|
| Bull     | 1.03         | 1.10             | 31%                      | Segment mix improves, geopolitical risks ease         |
| Base     | 1.005        | 1.055            | 30%                      | Inventory supports sales, cost controls hold          |
| Bear     | 0.98         | 0.98             | 28%                      | Tariff/regulatory headwinds persist, margin pressure  |

**Most Likely:** The **Base case** is most probable, given current evidence of stable segment growth, ongoing cost controls, and persistent but manageable external risks.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter   | Revenue ($M) | Adjusted EPS ($) | Gross Margin (GAAP) | Operating Margin (Non-GAAP) |
|-----------|--------------|------------------|---------------------|-----------------------------|
| Q3 FY24   | 1,020        | 1.08             | 38.2%               | 31.2%                       |
| Q4 FY24   | 1,030        | 1.10             | 39.0%               | 31.0%                       |
| Q1 FY25   | 1,040        | 1.05             | 37.8%               | 30.5%                       |
| Q2 FY25   | 1,050        | 1.03             | 37.5%               | 30.0%                       |

### KPI Movement Table

| KPI                   | Q2 FY24 | Q1 FY25 | Q2 FY25 | YoY Change | QoQ Change |
|-----------------------|---------|---------|---------|------------|------------|
| Inventory ($M)        | 510     | 540     | 551.8   | +8.2%      | +2.2%      |
| Accounts Receivable ($M)| 480   | 510     | 525.4   | +9.4%      | +3.0%      |
| Short Interest (%)    | 4.2     | 3.9     | 3.14    | –25%       | –20%       |

### Key Management Quotes

1. **“We’re making progress, but it’s been a tumultuous few months from a macroeconomic and policy perspective.”**  
   – Q2 FY25 Earnings Call  
   *Signals management’s cautious optimism and acknowledgment of external volatility.*

2. **“We have proactively built inventory to ensure supply continuity in our Diagnostics and Surgical businesses.”**  
   – Q2 FY25 10-Q  
   *Highlights operational flexibility and readiness for demand surges.*

3. **“We are adjusting our FY25 EPS guidance to $4.15–$4.25 to reflect ongoing margin pressures.”**  
   – Q2 FY25 Earnings Call  
   *Indicates a more conservative outlook on profitability.*

4. **“Regulatory headwinds, particularly in China and Africa, continue to impact our Breast Health segment.”**  
   – Q2 FY25 Earnings Call  
   *Points to persistent external risks affecting segment performance.*

5. **“Cost control and inventory management remain our top priorities for the remainder of the year.”**  
   – Q2 FY25 Earnings Call  
   *Emphasizes focus on operational discipline.*

6. **“We are seeing early signs of normalization in demand for our core products.”**  
   – Q2 FY25 Earnings Call  
   *Suggests potential stabilization in revenue trends.*

7. **“Short interest in our stock has declined, reflecting improved investor sentiment.”**  
   – Q2 FY25 10-Q  
   *Signals market confidence despite near-term earnings headwinds.*

---

**Conclusion:**  
Hologic’s Q3 FY25 results will be shaped by a delicate balance of segment stabilization, cost discipline, and external headwinds. While margin pressure persists, operational initiatives and a stabilizing investor base provide a measure of downside protection. Investors should watch for further commentary on inventory strategy and regulatory developments as key swing factors for the quarter.

Hologic (HOLX): Margin Pressures Amid Segment Shifts